通过天眼查大数据分析，江苏浩欧博生物医药股份有限公司共对外投资了6家企业，参与招投标项目181 次，知识产权方面有商标信息41条，专利信息112条，此外企业还拥有行政许可505个。 浩欧博最新一期业绩显示，截至2025一季报，公司营业总收入7761.28万元、同比减少9.33%，归属净利 润163.92万元，同比减少56.97%，扣非净利润24.06万元，同比减少90.69%，流动比率1.558、速动比率 0.878、资产负债率18.80%。 金融界消息 截至2025年8月1日收盘，浩欧博（688656）报收于121.4元，下跌3.13%，换手率2.99%，成 交量1.90万手，成交金额2.37亿元。 天眼查商业履历信息显示，江苏浩欧博生物医药股份有限公司，成立于2009年，位于苏州市，是一家以 从事医药制造业为主的企业。企业注册资本6305.8328万人民币，实缴资本6305.8328万人民币。公司法 定代表人为JOHN LI。 资金流向方面，今日主力资金净流入2236.55万元，占比成交额9.43%。其中，超大单净流入1301.13万 元、占成交额5.49%，大单净流入935.42万元、占成交额3.94% ...

Core Viewpoint - The AI Fund Agricultural Bank Healthcare Stock (000913) reported a profit of 142 million yuan for Q2 2025, with a weighted average profit per fund share of 0.1565 yuan, and a net asset value growth rate of 10.67% during the reporting period [2] Fund Performance - As of the end of Q2 2025, the fund's scale was 1.441 billion yuan [13] - The fund's unit net value as of July 17 was 1.875 yuan [2] - The fund's one-year cumulative net value growth rate was 38.71%, ranking 24 out of 53 comparable funds [2] - The fund's three-month cumulative net value growth rate was 26.79%, ranking 28 out of 54 comparable funds [2] - The fund's six-month cumulative net value growth rate was 42.95%, ranking 22 out of 54 comparable funds [2] - The fund's three-year cumulative net value growth rate was -9.44%, ranking 24 out of 46 comparable funds [2] Risk Metrics - The fund's three-year Sharpe ratio was -0.143, ranking 33 out of 46 comparable funds [7] - The maximum drawdown over the past three years was 40.52%, ranking 23 out of 46 comparable funds [8] - The highest single-quarter maximum drawdown occurred in Q1 2021, at 28.61% [8] Investment Strategy - The fund manager defined investment keywords for 2025 as innovation, medical AI, self-control, and state-owned enterprise reform [2] - The average stock position over the past three years was 90.34%, compared to the industry average of 88.16% [11] - The fund reached its highest stock position of 93.72% at the end of Q3 2020 and its lowest of 84.43% at the end of Q3 2024 [11] Top Holdings - As of the end of Q2 2025, the fund's top ten holdings included companies such as Heng Rui Medicine, Zejing Pharmaceutical, and Xinlitai [15]

Industry Overview - As of July 17, the medical device industry rose by 0.78%, with a net capital outflow of 178.58 million [1] - A total of 89 stocks in the sector increased, while 31 stocks decreased [1] Top Decliners - The top ten decliners in the sector included: - ST Kelly (-6.72%) - Haooubo (-4.36%) - Tailin Biology (-2.04%) - Mountain Outside Mountain (-1.71%) - Botuo Biology (-1.59%) - Yirui Technology (-1.35%) - DR Sanyou Medical (-1.31%) - Jihigh Development (-1.24%) - Anxu Biology (-1.21%) - Aidi Te (-0.89%) [1][1] Notable Gainers - Notable gainers included: - Anjisi: 7.36% increase with a net capital outflow of 12.83 million - Hualan Co.: 5.22% increase with a net capital outflow of 5.90 million - Xinmai Medical: 5.11% increase with a net capital inflow of 6.21 million - Nanwei Medical: 4.45% increase with a net capital inflow of 19.79 million [1][1][1] Market Sentiment - The overall market sentiment in the medical device sector showed a mixed performance with significant capital outflows from certain stocks while others attracted investment [1]

Market Review - The CITIC Pharmaceutical Index increased by 1.80%, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 CITIC first-level industry indices [5] - The top ten stocks by increase this week include Frontier Biologics-U, Medici, Lianhuan Pharmaceutical, Kangchen Pharmaceutical, and others, with Frontier Biologics-U leading at 41.43% [4][5] - The bottom ten stocks by decrease include ST Weiming, Shenzhou Cell, and Shuotai Shen, with ST Weiming dropping by 18.51% [4][5] Overall Viewpoint and Investment Themes - The current valuation of the pharmaceutical sector is at a low point, with public funds (excluding pharmaceutical funds) having low allocation to the sector. The company remains optimistic about the growth of the pharmaceutical industry by 2025, driven by macroeconomic factors and the demand from major categories [9] - In the innovative drug sector, there is a shift from quantity logic to quality logic, focusing on differentiated domestic and international pipelines. The company suggests paying more attention to products and companies that can ultimately realize profits [9] - In the medical device sector, there is a noticeable recovery in bidding volumes for imaging equipment, and the home medical device market is expected to benefit from subsidy policies. The company highlights the potential for import substitution and growth in the orthopedic sector post-collection [9] - The innovation chain (CXO + life sciences services) is expected to see a rebound in overseas investment and a bottoming out in domestic investment, with a potential return to high growth by 2025 [9] - The pharmaceutical industry is anticipated to enter a new growth cycle, with a focus on specialty raw materials and the expiration of patents leading to new growth opportunities [9] Industry and Company Events - The company highlights the innovative layout of traditional Chinese medicine enterprises, with several products in clinical II and III phases, including those targeting chronic insomnia and primary acute gouty arthritis [29][30] - Yunnan Baiyao has several drugs in various clinical stages, including those for prostate cancer and other conditions, indicating a robust pipeline [16][19] - The company emphasizes the importance of the blood products sector, which is expected to see significant growth due to relaxed approval processes and increased production capacity [14] - The innovative drug pipeline of Yiling Pharmaceutical focuses on cardiovascular, respiratory, and endocrine diseases, with multiple drugs in clinical trials [20][21]

Group 1 - The stock of Haooubo (688656) closed at 156.47 yuan on July 11, reaching the daily limit with a trading volume of 6.82 billion yuan and a turnover rate of 7.26% [2] - The stock was listed on the daily trading list due to a price increase of 15% at the close [2] - The top five trading departments accounted for a total transaction of 4.17 billion yuan, with a net purchase of 1.07 billion yuan [2] Group 2 - Among the top five buying departments, two were institutional special seats, with buying amounts of 83.68 million yuan and 50.80 million yuan respectively [3] - The Shanghai-Hong Kong Stock Connect was the second-largest buying department, with a purchase amount of 57.58 million yuan [3] - The leading selling department was Huatai Securities, with a selling amount of 50.61 million yuan [3]

Market Overview - The Shanghai Composite Index closed at 3510.18 points, up 0.01%, with a trading volume of 753.55 billion yuan [1] - The Shenzhen Component Index closed at 10696.10 points, up 0.61%, with a trading volume of 958.58 billion yuan [1] - The ChiNext Index closed at 2207.10 points, up 0.8%, with a trading volume of 460.02 billion yuan [1] - The STAR Market 50 Index closed at 994.45 points, up 1.48%, with a trading volume of 31.33 billion yuan [1] - The total trading volume of both markets reached 1712.13 billion yuan, an increase of 217.96 billion yuan compared to the previous trading day [1] Sector Performance - Strong sectors included securities, computers, steel, non-ferrous metals, pharmaceutical biology, national defense, home appliances, and machinery equipment [3] - Active concepts included rare earth permanent magnets, securities firms, digital currency, financial tax digitalization, small metals, and innovative drugs [3] - Weak sectors included banks, building materials, coal, textiles, education, and oil and petrochemicals [3] Individual Stock Performance - A total of 2769 stocks rose, while 2135 stocks fell, with 239 stocks remaining flat [3] - 68 stocks hit the daily limit up, while 14 stocks hit the daily limit down [3] - Notable stocks with consecutive limit ups included Guotou Zhonglu and Sifang New Materials, both with 5 consecutive limit ups [5] Fund Flow Analysis - The net outflow of main funds in the two markets was 14.038 billion yuan, with the ChiNext experiencing a net outflow of 3.261 billion yuan [6] - The computer sector saw the highest net inflow of main funds, amounting to 3.691 billion yuan [6] - A total of 1985 stocks received net inflows, with 73 stocks receiving over 1 billion yuan in net inflows [10] Institutional Activity - Institutions had a net buy of approximately 473 million yuan, with the highest net buy in Haooubo at about 134 million yuan [17] - The stocks with the highest net outflows included Tianfu Communication, with a net outflow of 611 million yuan [13]

Group 1 - The stock of Haobor reached a daily limit increase of 20%, with a trading volume of 682 million yuan and a turnover rate of 7.26% [1] - Data from the post-market dragon and tiger list indicates that the Shanghai Stock Connect dedicated seat purchased 57.58 million yuan [1] - Two institutional dedicated seats net bought 134 million yuan [1]

Core Viewpoint - The in vitro diagnostics sector experienced a slight increase of 0.24% on July 4, with a net outflow of funds amounting to 42.33 million [1] Group 1: Market Performance - A total of 18 stocks in the sector saw gains, while 49 stocks declined [1] - The top decliners included Dongfang Ocean (-6.51%), Xilong Scientific (-3.81%), and Nearshore Protein (-2.54%) [1][1] Group 2: Stock Performance - Notable gainers included: - Hotgen Biotech with a price of 194.81 and an increase of 20.08%, attracting a net fund inflow of 2.125 million [1] - Saily Medical at 21.08, up 10.02%, with a net inflow of 1.758 million [1] - Zhongyuan Union at 25.87, rising 9.99%, with a net inflow of 1.38 billion [1] - Decliners included: - Botao Biotech at 37.34, down 3.38%, with a net outflow of 1.087 million [1] - Maike Biotech at 7.99, down 2.44%, with a net inflow of 176.92 thousand [1]

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The healthcare sector has shown a mixed performance, with the Shenyin Wanguo Pharmaceutical Bio Index rising by 1.60% from June 23 to June 27, 2025, underperforming the CSI 300 Index by 0.35 percentage points [2][12]. - Year-to-date, the pharmaceutical sector has increased by 6.24%, outperforming the CSI 300 Index by 6.57 percentage points, ranking 11th among 31 sectors [2][14]. - As of June 27, 2025, the valuation of the pharmaceutical sector stands at 27.54 times (TTM overall method, excluding negative values), with a premium of 140.94% compared to the CSI 300 [2][17]. Summary by Sections 1. Market Performance - The pharmaceutical sector's performance from June 23 to June 27, 2025, was a 1.60% increase, ranking 23rd among 31 sectors [12]. - The year-to-date performance shows a 6.24% increase, ranking 11th among 31 sectors [14]. 2. Important Events - The National Healthcare Security Administration released the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment Application Guidelines," marking a significant step for commercial health insurance in the multi-level medical security system [4][21]. 3. Industry Perspective - The inclusion of the commercial insurance innovative drug directory indicates an enhanced role for commercial insurance in the multi-level medical security system, providing greater opportunities for the industry [5][22]. - The report expresses optimism for innovative drugs, overseas expansion, and the clearing of procurement in specific segments, suggesting a focus on companies involved in these areas [22].

证券代码：688656 证券简称：浩欧博 公告编号：2025-039 江苏浩欧博生物医药股份有限公司 2023 年限制性股票激励计划首次授予部分第二类激励 对象第一个归属期归属结果暨股票上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 421,412股。 本次股票上市流通总数为421,412股。 本次股票上市流通日期为2025 年 7 月 4 日。 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司相关业务规定，江苏浩欧博生物医药股份有限公司（以下简称 "公司"）于近日收到中国证券登记结算有限责任公司上海分公司出具的《证券 变更登记证明》，公司完成了 2023 年限制性股票激励计划首次授予部分第二类激 励对象第一个归属期的股份归属登记工作。现将有关情况公告如下： 3、2023 年 9 月 15 日至 2023 年 9 月 24 日，公司对本激励计划首次授予部分 激励对象的姓名和职务在公司内部进行了公示。 ...